5-7 December 2017

London, UK

Save £700 – Register Now

Workshop A
5th December, 2017

08.30 - 11.30

Designing Disease-Relevant In Vitro and Ex Vivo Models to Evaluate Signaling and Immunological Pathways and Therapeutics for Cancer

Workshop Leader: Dr Sophia N. Karagiannis, Reader in Translational Cancer Immunology Head of Cancer Antibody Discovery and Immunotherapy, King’s College London


In Vitro and Ex Vivo models provide a platform with which to explore signaling pathways and to identify therapeutic targets. Learn how to utilise disease-relevant models to boost your translational success.

This workshop will enable you to:

14 till 14

Dr Sophia N. Karagiannis, Reader in Translational Cancer Immunology Head of Cancer Antibody Discovery and Immunotherapy, King’s College London

8005 - Sophia K - King's

Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK, specialising focused on antibody therapies for solid tumours. Her group has developed therapeutic discovery to translation pathways, informed through dissecting B cells and the mechanisms of Th2 responses in cancer. In-house technologies include deriving antibodies from human B cells, expression systems enabling engineering antibodies of any specificity, class/subclass, and design of immunologically-relevant tumour models. The group is the first internationally to discover, evaluate and translate anti-tumour IgE class antibodies for oncology. Sophia is a founder of IGEM Ltd, the first immunooncology company dedicated to developing IgE therapeutic agents for cancer. She is a co-founder and serves as Secretary of the international AllergoOncology Task Force, a multidisciplinary consortium focused on the interface between allergies, IgE responses, and Th2 immunity, with cancer development, officially recognized by the European Academy of Allergy and Clinical Immunology since 2014.

Workshop B

12.00 - 14.30

Use of a Canine Tumor model for the Development of Immunotherapy against Solid Tumors

Workshop Leader: Michael Olin, Assistant Professor, Univeristy of Minnesota Workshop Leader: Elizabeth Pluhar, Professor, Univeristy of Minnesota


This workshop will enable you to:

  • Understand the similarity between Canine tumours and human tumours
  • Learn how spontaneous cancers in dogs represent attractive translational models

Session 11 till 12

Michael Olin, Assistant Professor, Univeristy of Minnesota

8005 - M.Olin

Dr. Olin is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology. Dr. Olin graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry and a BA in chemistry. After graduating, he worked in industry for 5 years before returning to the U of M to complete his PhD in Veterinary Medicine (Infectious Disease) in 2005. From 2006-2008 Dr. Olin did a postdoctoral fellowship with Dr. Philip Peterson studying the effects of opioids on tuberculosis meningitis, and from 2008-2011 he did a second postdoctoral fellowship with Dr. John Ohlfest in brain tumor immunotherapy. Dr. Olin’s scientific interest is defining the mechanism(s) of suppression inhibiting the ability to mount a tumoricidal response evident in the tumor draining lymph nodes and tumor environment and developed potential ways to modulate the immunosuppressive activity. Immunosuppressive tumor environment is a major hurdle for the immune system to overcome. Dr. Olin is focused on the development of inhibitors derived to overcome the suppressive tumor microenvironment.

Elizabeth Pluhar, Professor, Univeristy of Minnesota

Dr. Pluhar received her D.V.M. from Oregon State University in 1989. She earned a master of science degree in molecular biology from Northern Illinois University. In 1999, she earned a Ph.D. in veterinary sciences/comparative orthopaedics from the University of Wisconsin-Madison. Her research interests include improving total joint longevity, development of bone graft substitutes, the study of osteoclasts and bone graft incorporation, and the investigation of novel gene and immunotherapies for brain tumors. Dr. Pluhar is the director of the canine brain tumor program. She has led the development of use of naturally occurring spontaneous tumors in dogs to develop novel immunotherapies.

Workshop C
5th December, 2017

15.00 - 18.00

Humanised Mouse Models: Advantages and Pitfalls in Preclinical Assessment of Cancer Immunotherapy

Workshop Leader: Sara Colombetti, Ph.D, Head of Oncology Discovery Pharmacology, Roche Innovation Center


Humanised mouse models are now attracting increased attention in the immuno oncology field. Investigate this model as a unique tool for in vivo profiling of cancer immunotherapies

This workshop will enable you to:

  • Grasp an overview on the different types of humanised mouse models and how to best select preclinical design
  • Understand how best to apply humanised mouse models in the field of Cancer Immunotherapy
  • Learn about the Next generation improved humanised mouse models and how they can improve your translational success
  • Leave this workshop with actionable insights that will enable you to improve the key aspects of humanised mouse model design

Sara Colombetti, Ph.D, Head of Oncology Discovery Pharmacology, Roche Innovation Center

8005 - Sara Colombetti - Roche

Sara Colombetti received her Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy) focusing on the characterization of the molecular mechanisms of T  cell function and regulation. She then spent the next 5 years developing cancer CD8 T cell vaccines based on lentiviral vectors and VLP technologies at the Ludwig Institute for Cancer Research (Lausanne Branch, Switzerland) and at Cytos Biotechnology (Schlieren, Switzerland), respectively. In October 2009 she has joined the Oncology Discovery Pharmacology Department of the Roche Innovation Center Zurich (Switzerland), where she was first leading the In Vivo Models group, then the Immunopharmacodynamics and Bioanalytics & Pharmacokinetics Unit. Since the end of 2016 she has been leading the Oncology Discovery Pharmacology Department, responsible for all pre-clinical in vivo studies run within the Roche Innovation Center Zurich, focusing on cancer immunotherapy approaches.